Vrdn-002 (Viridian Therapeutics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameVrdn-002 (Viridian Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSomatomedins inhibitors
TargetsSomatomedins
Therapy Area/IndicationsGraves Ophthalmopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesViridian Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViridian Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsGraves Ophthalmopathy

Other Information

ATC CodeN/A
Related LinksN/A